JP7624922B2 - 胃腸疾患の治療のためのｊａｋ１経路阻害剤 - Google Patents

胃腸疾患の治療のためのｊａｋ１経路阻害剤 Download PDF

Info

Publication number
JP7624922B2
JP7624922B2 JP2021535585A JP2021535585A JP7624922B2 JP 7624922 B2 JP7624922 B2 JP 7624922B2 JP 2021535585 A JP2021535585 A JP 2021535585A JP 2021535585 A JP2021535585 A JP 2021535585A JP 7624922 B2 JP7624922 B2 JP 7624922B2
Authority
JP
Japan
Prior art keywords
azetidin
acetonitrile
pharma
pyrimidin
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021535585A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022514089A5 (https=
JPWO2020132210A5 (https=
JP2022514089A (ja
Inventor
イェレスワラム，クリシュナスワミー
スミス，ポール
エフ ホリス，グレゴリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of JP2022514089A publication Critical patent/JP2022514089A/ja
Publication of JP2022514089A5 publication Critical patent/JP2022514089A5/ja
Publication of JPWO2020132210A5 publication Critical patent/JPWO2020132210A5/ja
Application granted granted Critical
Publication of JP7624922B2 publication Critical patent/JP7624922B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021535585A 2018-12-19 2019-12-19 胃腸疾患の治療のためのｊａｋ１経路阻害剤 Active JP7624922B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862781877P 2018-12-19 2018-12-19
US62/781,877 2018-12-19
US201962854801P 2019-05-30 2019-05-30
US62/854,801 2019-05-30
US201962901377P 2019-09-17 2019-09-17
US62/901,377 2019-09-17
PCT/US2019/067418 WO2020132210A1 (en) 2018-12-19 2019-12-19 Jak1 pathway inhibitors for the treatment of gastrointestinal disease

Publications (4)

Publication Number Publication Date
JP2022514089A JP2022514089A (ja) 2022-02-09
JP2022514089A5 JP2022514089A5 (https=) 2022-12-26
JPWO2020132210A5 JPWO2020132210A5 (https=) 2022-12-26
JP7624922B2 true JP7624922B2 (ja) 2025-01-31

Family

ID=69326646

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021535585A Active JP7624922B2 (ja) 2018-12-19 2019-12-19 胃腸疾患の治療のためのｊａｋ１経路阻害剤

Country Status (15)

Country Link
US (2) US11596632B2 (https=)
EP (1) EP3897627A1 (https=)
JP (1) JP7624922B2 (https=)
KR (1) KR20210116487A (https=)
CN (1) CN113692278A (https=)
AU (1) AU2019403304B2 (https=)
CA (1) CA3123596A1 (https=)
IL (1) IL284034A (https=)
MA (1) MA54544A (https=)
MX (1) MX2021007260A (https=)
PH (1) PH12021551455A1 (https=)
SG (1) SG11202106470TA (https=)
TW (1) TWI884142B (https=)
UA (1) UA130221C2 (https=)
WO (1) WO2020132210A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3710431A4 (en) 2017-11-03 2021-07-07 Aclaris Therapeutics, Inc. SUBSTITUTED PYRROLOPYRIMIDINE-BASED JAK INHIBITORS AND THEIR MANUFACTURING AND USE PROCEDURES
WO2019191679A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Biomarkers for inflammatory skin disease
CA3097025A1 (en) 2018-04-13 2019-10-17 Incyte Corporation Biomarkers for graft-versus-host disease
WO2020033955A1 (en) 2018-08-10 2020-02-13 Aclaris Therapeutics, Inc. Pyrrolopyrimidine itk inhibitors
CA3117969A1 (en) 2018-10-31 2020-05-07 Incyte Corporation Combination therapy for treatment of hematological diseases
CA3123596A1 (en) 2018-12-19 2020-06-25 Incyte Corporation Jak1 pathway inhibitors for the treatment of gastrointestinal disease
MA55201A (fr) 2019-03-05 2022-01-12 Incyte Corp Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire
EP4041204A1 (en) 2019-10-10 2022-08-17 Incyte Corporation Biomarkers for graft-versus-host disease
US12360120B2 (en) 2019-10-10 2025-07-15 Incyte Corporation Biomarkers for graft-versus-host disease
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
EP4351584A4 (en) * 2021-06-07 2025-04-23 The Regents of the University of California COMPOSITIONS AND METHODS FOR TREATING CELIAC DISEASE
EP4615440A1 (en) * 2022-11-08 2025-09-17 Aclaris Therapeutics, Inc. Pyrrolopyrimidine compositions for treatment of itk mediated conditions
WO2025144781A1 (en) * 2023-12-28 2025-07-03 Aclaris Therapeutics, Inc. Crystalline polymorph of an itk inhibitor
CN120699157B (zh) * 2025-07-16 2025-12-16 安康市中心医院 一种治疗溃疡性结肠炎的恢复肠屏障功能抗体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013522214A (ja) 2010-03-10 2013-06-13 インサイト・コーポレイション Ｊａｋ１阻害剤としてのピペリジン−４−イルアゼチジン誘導体
WO2017091544A1 (en) 2015-11-24 2017-06-01 Theravance Biopharma R&D Ip, Llc Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease
WO2018112245A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2376596C (en) 1999-06-25 2009-10-06 Genentech, Inc. Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies
ATE273695T1 (de) 2000-06-28 2004-09-15 Smithkline Beecham Plc Nassvermahlung
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
ES2392525T3 (es) 2002-07-15 2012-12-11 F. Hoffmann-La Roche Ag Tratamiento del cáncer con el anticuerpo dirigido contra ErbB2 rhuMAb 2C4
JP5775070B2 (ja) 2009-05-22 2015-09-09 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ ヤヌスキナーゼ阻害剤としてのピラゾール−４−イル−ピロロ［２，３−ｄ］ピリミジンおよびピロール−３−イル−ピロロ［２，３−ｄ］ピリミジンのＮ−（ヘテロ）アリール−ピロリジン誘導体
AR078012A1 (es) 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
CN104918945B (zh) 2012-11-01 2018-01-05 因赛特公司 作为jak抑制剂的三环稠合噻吩衍生物
WO2014138168A1 (en) 2013-03-06 2014-09-12 Incyte Corporation Processes and intermediates for making a jak inhibitor
SMT201900223T1 (it) 2013-05-17 2019-07-11 Incyte Corp Sale di bipirazolo come inibitore di jak
SG10201801069QA (en) * 2013-08-07 2018-03-28 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
CN106687462A (zh) 2014-04-30 2017-05-17 因赛特公司 Jak1抑制剂的制备方法以及其新形式
WO2018111327A1 (en) * 2016-12-14 2018-06-21 Progenity Inc. Methods and ingestible devices for the regio-specific release of jak inhibitors at the site of gastrointestinal tract disease
CA3123596A1 (en) 2018-12-19 2020-06-25 Incyte Corporation Jak1 pathway inhibitors for the treatment of gastrointestinal disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013522214A (ja) 2010-03-10 2013-06-13 インサイト・コーポレイション Ｊａｋ１阻害剤としてのピペリジン−４−イルアゼチジン誘導体
WO2017091544A1 (en) 2015-11-24 2017-06-01 Theravance Biopharma R&D Ip, Llc Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease
WO2018112245A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MARJORIE ARGOLLO; ET AL，NOVEL THERAPEUTIC TARGETS FOR INFLAMMATORY BOWEL DISEASE，JOURNAL OF AUTOIMMUNITY，2017年07月12日，VOL:85，PAGE(S):103-116，http://dx.doi.org/10.1016/j.jaut.2017.07.004
WILLIAM J. SANDBORN; ET AL，TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, IN ACTIVE ULCERATIVE COLITIS，THE NEW ENGLAND JOURNAL OF MEDICINE，米国，MASSACHUSETTS MEDICAL SOCIETY，2012年07月31日，VOL:367, NR:7，PAGE(S):616-624，http://dx.doi.org/10.1056/NEJMoa1112168

Also Published As

Publication number Publication date
US12150943B2 (en) 2024-11-26
KR20210116487A (ko) 2021-09-27
TW202038944A (zh) 2020-11-01
US20200197399A1 (en) 2020-06-25
AU2019403304A1 (en) 2021-07-08
CN113692278A (zh) 2021-11-23
SG11202106470TA (en) 2021-07-29
TWI884142B (zh) 2025-05-21
US20230172939A1 (en) 2023-06-08
CA3123596A1 (en) 2020-06-25
AU2019403304B2 (en) 2025-09-04
PH12021551455A1 (en) 2022-04-18
WO2020132210A1 (en) 2020-06-25
MA54544A (fr) 2021-10-27
EP3897627A1 (en) 2021-10-27
IL284034A (en) 2021-08-31
JP2022514089A (ja) 2022-02-09
UA130221C2 (uk) 2025-12-24
US11596632B2 (en) 2023-03-07
MX2021007260A (es) 2021-09-08

Similar Documents

Publication Publication Date Title
JP7624922B2 (ja) 胃腸疾患の治療のためのｊａｋ１経路阻害剤
KR102925957B1 (ko) 사이토카인-관련 장애의 치료를 위한 jak1 경로 억제제
JP2025087734A (ja) 慢性肺同種移植片機能不全の治療のためのｊａｋ１経路阻害剤
JP2022533368A (ja) Ｍｋ２媒介性障害の治療方法
JP2016516815A (ja) １−エチル−７−（２−メチル−６−（１Ｈ−１，２，４−トリアゾール−３−イル）ピリジン−３−イル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オンに関する医薬製剤、プロセス、固形形態、及び使用方法
JP2023506118A (ja) 皮膚エリテマトーデス及び扁平苔癬（ｌｐ）の治療のためのｊａｋ１阻害剤の使用
KR20240009964A (ko) 결절성 양진 치료를 위한 jak1 경로 억제제
EA048119B1 (ru) Ингибиторы пути jak1 для лечения заболевания желудочно-кишечного тракта
US20240307353A1 (en) Jak1 pathway inhibitors for the treatment of asthma
KR20250156781A (ko) 건선의 치료에 사용하기 위한 인터루킨-23 수용체 길항제 펩티드
CN119816304A (zh) Nlrp3抑制剂的给药方案
EA050837B1 (ru) Ингибиторы пути jak1, предназначенные для лечения связанных с цитокинами нарушений
EA042956B1 (ru) Ингибиторы пути jak1, предназначенные для лечения связанных с цитокинами нарушений
JP2004083499A (ja) 早産防止剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240606

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241126

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250114

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250121

R150 Certificate of patent or registration of utility model

Ref document number: 7624922

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150